Clinical Trial Update: Efficacy and Tolerability of BAF312 in Patients With Polymyositis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and tolerability of BAF312 in polymyositis; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyositis

Drugs mentioned

• BAF312 (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polymyositis | Phase 2 | Status: TERMINATED | Results posted: 2018-01-04